Bevacizumab

Generic Name: Bevacizumab

Brand Names: Avastin, Mvasi, Oyavas, Alymsys, Aybintio, Abevmy, Vegzelma, Onbevzi, Zirabev, Lytenava, Avzivi

Drug Type: Biotech

Chemical Formula: -

CAS Number: 216974-75-3

Unique Ingredient Identifier: 2S9ZZM9Q9V

Background: There is a great deal of evidence indicating that vascular endothelial growth factor (VEGF) is important for the survival and proliferation of cancer cells. VEGF plays an important role in angiogenesis, lymphangiogenesis, and tumor growth, which are all factors that contribute to its attractiveness as a therapeutic target for anti-cancer therapies.
...

Indication: As a vascular endothelial growth factor (VEGF) inhibitor, bevacizumab is used in several chemotherapy regimens to treat metastatic colorectal cancer; metastatic, unresectable, locally advanced or recurrent non-squamous non-small cell lung cancer; metastatic renal cell carcinoma; metastatic, persistent, or recurrent cervical cancer; primary peritoneal cancer;...

Associated Conditions: Metastatic Breast Cancer, Metastatic Cervical Cancer, Metastatic Colorectal Cancer (CRC), Metastatic Non-squamous Non Small Cell Lung Cancer, Metastatic Renal Cell Carcinoma ( mRCC), Persistent Cervical Cancer, Recurrent Cervical Cancer, Recurrent Glioblastoma, Relapsed Glioblastoma, Stage III Fallopian Tube Cancer, Stage III Ovarian Epithelial Cancer, Stage III Primary Peritoneal Cancer, Stage IV Fallopian Tube Cancer, Stage IV Ovarian Epithelial Cancer, Stage IV Primary Peritoneal Cancer, Locally advanced nonsquamous non-small cell lung cancer, Recurrent Non-Squamous Non-Small Cell Lung Cancer, Recurrent Platinum-Sensitive Epithelial Ovarian Cancer, Recurrent Platinum-resistant Epithelial Ovarian Cancer, Recurrent platinum drug resistant Fallopian tube cancer, Recurrent platinum drug resistant primary peritoneal cancer, Recurrent platinum sensitive primary peritoneal cancer, Recurrent platinum-sensitive fallopian tube cancer, Unresectable Non-Squamous Non-Small Cell Lung Cancer, Unresectable, advanced Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC)

Associated Therapies: First Line Chemotherapy, First or Second Line Therapy, Second Line Treatment

Clinical Trials

Capecitabine, Oxaliplatin, Bevacizumab and Radiation Therapy in Patients With Biliary Tract and Gallbladder Cancer

Phase 2

Completed

Conditions: Biliary Tract Cancer
Gallbladder Adenocarcinoma

Interventions: Drug: Capecitabine
Drug: Oxaliplatin
Drug: Bevacizumab
Procedure: Radiation therapy

First Posted Date: 2005-09-02

Last Posted Date: 2018-04-25

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 8

Registration Number: NCT00142480

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

Gemcitabine, Oxaliplatin in Combination With Bevacizumab in Patients With Hepatocellular Carcinoma

Phase 2

Completed

Conditions: Hepatocellular Carcinoma

Interventions: Drug: Gemcitabine
Drug: Oxaliplatin
Drug: Bevacizumab

First Posted Date: 2005-09-02

Last Posted Date: 2014-03-18

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 33

Registration Number: NCT00142467

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

Angiogenic and EGFR Blockade With Curative Chemoradiation for Advanced Head and Neck Cancer

Early Phase 1

Completed

Conditions: Head and Neck Cancer
Pharynx Cancer

Interventions: Radiation: Chemoradiotherapy
Drug: Cisplatin
Drug: Bevacizumab
Drug: Erlotinib

First Posted Date: 2005-09-01

Last Posted Date: 2013-01-18

Lead Sponsor: David M. Brizel, MD

Target Recruit Count: 28

Registration Number: NCT00140556

Locations: 🇺🇸
Department of Radiation Oncology; Duke University Medical Center, Durham, North Carolina, United States

Efficacy of Bevacizumab Monotherapy in Treatment of Metastatic Melanoma

Phase 2

Completed

Conditions: Metastatic Melanoma

Interventions: Drug: Bevacizumab

First Posted Date: 2005-08-31

Last Posted Date: 2015-08-27

Lead Sponsor: Haukeland University Hospital

Target Recruit Count: 35

Registration Number: NCT00139360

Locations: 🇳🇴
Department of Oncology, Haukeland University Hospital, Bergen, Norway

Bevacizumab in Combination With Temozolomide in Patients With Neuroendocrine Tumors

Phase 2

Completed

Conditions: Neuroendocrine Tumors

First Posted Date: 2005-08-30

Last Posted Date: 2013-04-09

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 34

Registration Number: NCT00137774

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Insitute, Boston, Massachusetts, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

Avastin and Taxotere for Esophagogastric Cancer

Phase 2

Completed

Conditions: Esophageal Cancer
Gastric Cancer

First Posted Date: 2005-08-30

Last Posted Date: 2018-11-01

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 42

Registration Number: NCT00137813

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

Bevacizumab (Avastin) and Erlotinib (Tarceva) in Previously Treated Mesothelioma

Phase 2

Completed

Conditions: Mesothelioma

First Posted Date: 2005-08-30

Last Posted Date: 2011-12-26

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 37

Registration Number: NCT00137826

Locations: 🇺🇸
The University of Chicago, Chicago, Illinois, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

A Study to Evaluate the Efficacy of Bevacizumab in Combination With Tarceva for Advanced Non-Small Cell Lung Cancer

Phase 3

Completed

Conditions: Non-Small Cell Lung Cancer

Interventions: Drug: erlotinib HCl
Drug: bevacizumab
Drug: placebo

First Posted Date: 2005-08-16

Last Posted Date: 2021-01-14

Lead Sponsor: Genentech, Inc.

Target Recruit Count: 636

Registration Number: NCT00130728

Locations: 🇺🇸
Kaiser Permanente - Vallejo, Vallejo, California, United States
🇺🇸
Anne Arundel Health System Research Instit-Annapolis Oncology Ctr, Annapolis, Maryland, United States
🇺🇸
University Cancer & Blood Center, LLC; Research, Athens, Georgia, United States

and more 1 locations